Medical Care

Global Rectal Cancer Therapeutics Market Research Report 2024

Rectal cancer is a disease in which malignant (cancer) cells form in the tissues of the rectum.

The global Rectal Cancer Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

North American market for Rectal Cancer Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Rectal Cancer Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for Rectal Cancer Therapeutics in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of Rectal Cancer Therapeutics include Eli Lilly and Company, Taiwan Liposome, Genentech, Sanofi-aventis Groupe, Merck, Bristol-Myers Squibb, Hutchison MediPharma, Seattle Genetics and Advaxis, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Rectal Cancer Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rectal Cancer Therapeutics.

Report Scope

The Rectal Cancer Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Rectal Cancer Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Rectal Cancer Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

Eli Lilly and Company

Taiwan Liposome

Genentech

Sanofi-aventis Groupe

Merck

Bristol-Myers Squibb

Hutchison MediPharma

Seattle Genetics

Advaxis

Pfizer

AstraZeneca

Segment by Type

Medicine

Surgery

Other

Segment by Application

Hospital

Clinic

Other

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Rectal Cancer Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 12: The main points and conclusions of the report.

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Rectal Cancer Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Medicine

1.2.3 Surgery

1.2.4 Other

1.3 Market by Application

1.3.1 Global Rectal Cancer Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Other

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Rectal Cancer Therapeutics Market Perspective (2019-2030)

2.2 Rectal Cancer Therapeutics Growth Trends by Region

2.2.1 Global Rectal Cancer Therapeutics Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Rectal Cancer Therapeutics Historic Market Size by Region (2019-2024)

2.2.3 Rectal Cancer Therapeutics Forecasted Market Size by Region (2025-2030)

2.3 Rectal Cancer Therapeutics Market Dynamics

2.3.1 Rectal Cancer Therapeutics Industry Trends

2.3.2 Rectal Cancer Therapeutics Market Drivers

2.3.3 Rectal Cancer Therapeutics Market Challenges

2.3.4 Rectal Cancer Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Rectal Cancer Therapeutics Players by Revenue

3.1.1 Global Top Rectal Cancer Therapeutics Players by Revenue (2019-2024)

3.1.2 Global Rectal Cancer Therapeutics Revenue Market Share by Players (2019-2024)

3.2 Global Rectal Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Rectal Cancer Therapeutics Revenue

3.4 Global Rectal Cancer Therapeutics Market Concentration Ratio

3.4.1 Global Rectal Cancer Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Rectal Cancer Therapeutics Revenue in 2023

3.5 Rectal Cancer Therapeutics Key Players Head office and Area Served

3.6 Key Players Rectal Cancer Therapeutics Product Solution and Service

3.7 Date of Enter into Rectal Cancer Therapeutics Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Rectal Cancer Therapeutics Breakdown Data by Type

4.1 Global Rectal Cancer Therapeutics Historic Market Size by Type (2019-2024)

4.2 Global Rectal Cancer Therapeutics Forecasted Market Size by Type (2025-2030)

5 Rectal Cancer Therapeutics Breakdown Data by Application

5.1 Global Rectal Cancer Therapeutics Historic Market Size by Application (2019-2024)

5.2 Global Rectal Cancer Therapeutics Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Rectal Cancer Therapeutics Market Size (2019-2030)

6.2 North America Rectal Cancer Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Rectal Cancer Therapeutics Market Size by Country (2019-2024)

6.4 North America Rectal Cancer Therapeutics Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Rectal Cancer Therapeutics Market Size (2019-2030)

7.2 Europe Rectal Cancer Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Rectal Cancer Therapeutics Market Size by Country (2019-2024)

7.4 Europe Rectal Cancer Therapeutics Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Rectal Cancer Therapeutics Market Size (2019-2030)

8.2 Asia-Pacific Rectal Cancer Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Rectal Cancer Therapeutics Market Size by Region (2019-2024)

8.4 Asia-Pacific Rectal Cancer Therapeutics Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Rectal Cancer Therapeutics Market Size (2019-2030)

9.2 Latin America Rectal Cancer Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Rectal Cancer Therapeutics Market Size by Country (2019-2024)

9.4 Latin America Rectal Cancer Therapeutics Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Rectal Cancer Therapeutics Market Size (2019-2030)

10.2 Middle East & Africa Rectal Cancer Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Rectal Cancer Therapeutics Market Size by Country (2019-2024)

10.4 Middle East & Africa Rectal Cancer Therapeutics Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Eli Lilly and Company

11.1.1 Eli Lilly and Company Company Detail

11.1.2 Eli Lilly and Company Business Overview

11.1.3 Eli Lilly and Company Rectal Cancer Therapeutics Introduction

11.1.4 Eli Lilly and Company Revenue in Rectal Cancer Therapeutics Business (2019-2024)

11.1.5 Eli Lilly and Company Recent Development

11.2 Taiwan Liposome

11.2.1 Taiwan Liposome Company Detail

11.2.2 Taiwan Liposome Business Overview

11.2.3 Taiwan Liposome Rectal Cancer Therapeutics Introduction

11.2.4 Taiwan Liposome Revenue in Rectal Cancer Therapeutics Business (2019-2024)

11.2.5 Taiwan Liposome Recent Development

11.3 Genentech

11.3.1 Genentech Company Detail

11.3.2 Genentech Business Overview

11.3.3 Genentech Rectal Cancer Therapeutics Introduction

11.3.4 Genentech Revenue in Rectal Cancer Therapeutics Business (2019-2024)

11.3.5 Genentech Recent Development

11.4 Sanofi-aventis Groupe

11.4.1 Sanofi-aventis Groupe Company Detail

11.4.2 Sanofi-aventis Groupe Business Overview

11.4.3 Sanofi-aventis Groupe Rectal Cancer Therapeutics Introduction

11.4.4 Sanofi-aventis Groupe Revenue in Rectal Cancer Therapeutics Business (2019-2024)

11.4.5 Sanofi-aventis Groupe Recent Development

11.5 Merck

11.5.1 Merck Company Detail

11.5.2 Merck Business Overview

11.5.3 Merck Rectal Cancer Therapeutics Introduction

11.5.4 Merck Revenue in Rectal Cancer Therapeutics Business (2019-2024)

11.5.5 Merck Recent Development

11.6 Bristol-Myers Squibb

11.6.1 Bristol-Myers Squibb Company Detail

11.6.2 Bristol-Myers Squibb Business Overview

11.6.3 Bristol-Myers Squibb Rectal Cancer Therapeutics Introduction

11.6.4 Bristol-Myers Squibb Revenue in Rectal Cancer Therapeutics Business (2019-2024)

11.6.5 Bristol-Myers Squibb Recent Development

11.7 Hutchison MediPharma

11.7.1 Hutchison MediPharma Company Detail

11.7.2 Hutchison MediPharma Business Overview

11.7.3 Hutchison MediPharma Rectal Cancer Therapeutics Introduction

11.7.4 Hutchison MediPharma Revenue in Rectal Cancer Therapeutics Business (2019-2024)

11.7.5 Hutchison MediPharma Recent Development

11.8 Seattle Genetics

11.8.1 Seattle Genetics Company Detail

11.8.2 Seattle Genetics Business Overview

11.8.3 Seattle Genetics Rectal Cancer Therapeutics Introduction

11.8.4 Seattle Genetics Revenue in Rectal Cancer Therapeutics Business (2019-2024)

11.8.5 Seattle Genetics Recent Development

11.9 Advaxis

11.9.1 Advaxis Company Detail

11.9.2 Advaxis Business Overview

11.9.3 Advaxis Rectal Cancer Therapeutics Introduction

11.9.4 Advaxis Revenue in Rectal Cancer Therapeutics Business (2019-2024)

11.9.5 Advaxis Recent Development

11.10 Pfizer

11.10.1 Pfizer Company Detail

11.10.2 Pfizer Business Overview

11.10.3 Pfizer Rectal Cancer Therapeutics Introduction

11.10.4 Pfizer Revenue in Rectal Cancer Therapeutics Business (2019-2024)

11.10.5 Pfizer Recent Development

11.11 AstraZeneca

11.11.1 AstraZeneca Company Detail

11.11.2 AstraZeneca Business Overview

11.11.3 AstraZeneca Rectal Cancer Therapeutics Introduction

11.11.4 AstraZeneca Revenue in Rectal Cancer Therapeutics Business (2019-2024)

11.11.5 AstraZeneca Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

Table 1. Global Rectal Cancer Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Medicine

Table 3. Key Players of Surgery

Table 4. Key Players of Other

Table 5. Global Rectal Cancer Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Rectal Cancer Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global Rectal Cancer Therapeutics Market Size by Region (2019-2024) & (US$ Million)

Table 8. Global Rectal Cancer Therapeutics Market Share by Region (2019-2024)

Table 9. Global Rectal Cancer Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 10. Global Rectal Cancer Therapeutics Market Share by Region (2025-2030)

Table 11. Rectal Cancer Therapeutics Market Trends

Table 12. Rectal Cancer Therapeutics Market Drivers

Table 13. Rectal Cancer Therapeutics Market Challenges

Table 14. Rectal Cancer Therapeutics Market Restraints

Table 15. Global Rectal Cancer Therapeutics Revenue by Players (2019-2024) & (US$ Million)

Table 16. Global Rectal Cancer Therapeutics Market Share by Players (2019-2024)

Table 17. Global Top Rectal Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Rectal Cancer Therapeutics as of 2023)

Table 18. Ranking of Global Top Rectal Cancer Therapeutics Companies by Revenue (US$ Million) in 2023

Table 19. Global 5 Largest Players Market Share by Rectal Cancer Therapeutics Revenue (CR5 and HHI) & (2019-2024)

Table 20. Key Players Headquarters and Area Served

Table 21. Key Players Rectal Cancer Therapeutics Product Solution and Service

Table 22. Date of Enter into Rectal Cancer Therapeutics Market

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Rectal Cancer Therapeutics Market Size by Type (2019-2024) & (US$ Million)

Table 25. Global Rectal Cancer Therapeutics Revenue Market Share by Type (2019-2024)

Table 26. Global Rectal Cancer Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 27. Global Rectal Cancer Therapeutics Revenue Market Share by Type (2025-2030)

Table 28. Global Rectal Cancer Therapeutics Market Size by Application (2019-2024) & (US$ Million)

Table 29. Global Rectal Cancer Therapeutics Revenue Market Share by Application (2019-2024)

Table 30. Global Rectal Cancer Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 31. Global Rectal Cancer Therapeutics Revenue Market Share by Application (2025-2030)

Table 32. North America Rectal Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 33. North America Rectal Cancer Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 34. North America Rectal Cancer Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 35. Europe Rectal Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 36. Europe Rectal Cancer Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 37. Europe Rectal Cancer Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 38. Asia-Pacific Rectal Cancer Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 39. Asia-Pacific Rectal Cancer Therapeutics Market Size by Region (2019-2024) & (US$ Million)

Table 40. Asia-Pacific Rectal Cancer Therapeutics Market Size by Region (2025-2030) & (US$ Million)

Table 41. Latin America Rectal Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 42. Latin America Rectal Cancer Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 43. Latin America Rectal Cancer Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 44. Middle East & Africa Rectal Cancer Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 45. Middle East & Africa Rectal Cancer Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 46. Middle East & Africa Rectal Cancer Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 47. Eli Lilly and Company Company Detail

Table 48. Eli Lilly and Company Business Overview

Table 49. Eli Lilly and Company Rectal Cancer Therapeutics Product

Table 50. Eli Lilly and Company Revenue in Rectal Cancer Therapeutics Business (2019-2024) & (US$ Million)

Table 51. Eli Lilly and Company Recent Development

Table 52. Taiwan Liposome Company Detail

Table 53. Taiwan Liposome Business Overview

Table 54. Taiwan Liposome Rectal Cancer Therapeutics Product

Table 55. Taiwan Liposome Revenue in Rectal Cancer Therapeutics Business (2019-2024) & (US$ Million)

Table 56. Taiwan Liposome Recent Development

Table 57. Genentech Company Detail

Table 58. Genentech Business Overview

Table 59. Genentech Rectal Cancer Therapeutics Product

Table 60. Genentech Revenue in Rectal Cancer Therapeutics Business (2019-2024) & (US$ Million)

Table 61. Genentech Recent Development

Table 62. Sanofi-aventis Groupe Company Detail

Table 63. Sanofi-aventis Groupe Business Overview

Table 64. Sanofi-aventis Groupe Rectal Cancer Therapeutics Product

Table 65. Sanofi-aventis Groupe Revenue in Rectal Cancer Therapeutics Business (2019-2024) & (US$ Million)

Table 66. Sanofi-aventis Groupe Recent Development

Table 67. Merck Company Detail

Table 68. Merck Business Overview

Table 69. Merck Rectal Cancer Therapeutics Product

Table 70. Merck Revenue in Rectal Cancer Therapeutics Business (2019-2024) & (US$ Million)

Table 71. Merck Recent Development

Table 72. Bristol-Myers Squibb Company Detail

Table 73. Bristol-Myers Squibb Business Overview

Table 74. Bristol-Myers Squibb Rectal Cancer Therapeutics Product

Table 75. Bristol-Myers Squibb Revenue in Rectal Cancer Therapeutics Business (2019-2024) & (US$ Million)

Table 76. Bristol-Myers Squibb Recent Development

Table 77. Hutchison MediPharma Company Detail

Table 78. Hutchison MediPharma Business Overview

Table 79. Hutchison MediPharma Rectal Cancer Therapeutics Product

Table 80. Hutchison MediPharma Revenue in Rectal Cancer Therapeutics Business (2019-2024) & (US$ Million)

Table 81. Hutchison MediPharma Recent Development

Table 82. Seattle Genetics Company Detail

Table 83. Seattle Genetics Business Overview

Table 84. Seattle Genetics Rectal Cancer Therapeutics Product

Table 85. Seattle Genetics Revenue in Rectal Cancer Therapeutics Business (2019-2024) & (US$ Million)

Table 86. Seattle Genetics Recent Development

Table 87. Advaxis Company Detail

Table 88. Advaxis Business Overview

Table 89. Advaxis Rectal Cancer Therapeutics Product

Table 90. Advaxis Revenue in Rectal Cancer Therapeutics Business (2019-2024) & (US$ Million)

Table 91. Advaxis Recent Development

Table 92. Pfizer Company Detail

Table 93. Pfizer Business Overview

Table 94. Pfizer Rectal Cancer Therapeutics Product

Table 95. Pfizer Revenue in Rectal Cancer Therapeutics Business (2019-2024) & (US$ Million)

Table 96. Pfizer Recent Development

Table 97. AstraZeneca Company Detail

Table 98. AstraZeneca Business Overview

Table 99. AstraZeneca Rectal Cancer Therapeutics Product

Table 100. AstraZeneca Revenue in Rectal Cancer Therapeutics Business (2019-2024) & (US$ Million)

Table 101. AstraZeneca Recent Development

Table 102. Research Programs/Design for This Report

Table 103. Key Data Information from Secondary Sources

Table 104. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Rectal Cancer Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Rectal Cancer Therapeutics Market Share by Type: 2023 VS 2030

Figure 3. Medicine Features

Figure 4. Surgery Features

Figure 5. Other Features

Figure 6. Global Rectal Cancer Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 7. Global Rectal Cancer Therapeutics Market Share by Application: 2023 VS 2030

Figure 8. Hospital Case Studies

Figure 9. Clinic Case Studies

Figure 10. Other Case Studies

Figure 11. Rectal Cancer Therapeutics Report Years Considered

Figure 12. Global Rectal Cancer Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 13. Global Rectal Cancer Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global Rectal Cancer Therapeutics Market Share by Region: 2023 VS 2030

Figure 15. Global Rectal Cancer Therapeutics Market Share by Players in 2023

Figure 16. Global Top Rectal Cancer Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Rectal Cancer Therapeutics as of 2023)

Figure 17. The Top 10 and 5 Players Market Share by Rectal Cancer Therapeutics Revenue in 2023

Figure 18. North America Rectal Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 19. North America Rectal Cancer Therapeutics Market Share by Country (2019-2030)

Figure 20. United States Rectal Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. Canada Rectal Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Europe Rectal Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Europe Rectal Cancer Therapeutics Market Share by Country (2019-2030)

Figure 24. Germany Rectal Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. France Rectal Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. U.K. Rectal Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Italy Rectal Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Russia Rectal Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Nordic Countries Rectal Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Asia-Pacific Rectal Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Asia-Pacific Rectal Cancer Therapeutics Market Share by Region (2019-2030)

Figure 32. China Rectal Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Japan Rectal Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. South Korea Rectal Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Southeast Asia Rectal Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. India Rectal Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Australia Rectal Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Latin America Rectal Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Latin America Rectal Cancer Therapeutics Market Share by Country (2019-2030)

Figure 40. Mexico Rectal Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Brazil Rectal Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Middle East & Africa Rectal Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Middle East & Africa Rectal Cancer Therapeutics Market Share by Country (2019-2030)

Figure 44. Turkey Rectal Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Saudi Arabia Rectal Cancer Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Eli Lilly and Company Revenue Growth Rate in Rectal Cancer Therapeutics Business (2019-2024)

Figure 47. Taiwan Liposome Revenue Growth Rate in Rectal Cancer Therapeutics Business (2019-2024)

Figure 48. Genentech Revenue Growth Rate in Rectal Cancer Therapeutics Business (2019-2024)

Figure 49. Sanofi-aventis Groupe Revenue Growth Rate in Rectal Cancer Therapeutics Business (2019-2024)

Figure 50. Merck Revenue Growth Rate in Rectal Cancer Therapeutics Business (2019-2024)

Figure 51. Bristol-Myers Squibb Revenue Growth Rate in Rectal Cancer Therapeutics Business (2019-2024)

Figure 52. Hutchison MediPharma Revenue Growth Rate in Rectal Cancer Therapeutics Business (2019-2024)

Figure 53. Seattle Genetics Revenue Growth Rate in Rectal Cancer Therapeutics Business (2019-2024)

Figure 54. Advaxis Revenue Growth Rate in Rectal Cancer Therapeutics Business (2019-2024)

Figure 55. Pfizer Revenue Growth Rate in Rectal Cancer Therapeutics Business (2019-2024)

Figure 56. AstraZeneca Revenue Growth Rate in Rectal Cancer Therapeutics Business (2019-2024)

Figure 57. Bottom-up and Top-down Approaches for This Report

Figure 58. Data Triangulation

Figure 59. Key Executives Interviewed

Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies